Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuPharma ( (GB:IMM) ) has shared an update.
ImmuPharma PLC has launched a new corporate website, highlighting its P140 autoimmune platform, which offers a novel approach to treating autoimmune diseases by restoring immune balance. The company is also developing a companion diagnostic tool for precise patient monitoring and is actively seeking partnerships to commercialize its P140 platform, with plans to complete a deal by the end of 2025. Financially, ImmuPharma has extended its cash runway into the second half of 2026 and aims to strengthen its cash position through potential partnerships.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
Average Trading Volume: 11,597,201
Technical Sentiment Signal: Buy
Current Market Cap: £60.83M
Learn more about IMM stock on TipRanks’ Stock Analysis page.